Synthesis of eribulin mesylate

A technology of methanesulfonic acid and methyl, which is applied in the field of preparation of key intermediates of the complex natural modified drug Eribulin mesilate, which can solve the problems of limited sample amount and slow research and development progress

Active Publication Date: 2021-09-07
WISDOM PHARM CO LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, due to the limited amount of samples isolated from spong

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Synthesis of eribulin mesylate
  • Synthesis of eribulin mesylate
  • Synthesis of eribulin mesylate

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] Embodiment one: the preparation of formula II compound (using piperidine hydrochloride) (yield 85%)

[0017]

[0018] Dissolve the compound of formula I (460.0mg, 0.348mmol) in THF (21.5mL) at 20-25°C, add piperidine hydrochloride (211.6mg, 1.74mmol) and TBAF (1M THF solution, 3.48mL, 3.48mmol ), keep stirring at this temperature for 20h. The reaction solution was concentrated under reduced pressure at 30°C to remove THF, then dissolved in a small amount of DCM, and purified by column chromatography (EA / n-Hept=1 / 1→EA→MeOH / EA=1 / 15) to obtain the target compound of formula II (white solid, 222.3 mg, 85.3%). ESI-MS:C 40 h 60 o 13 Calculated value: 748.4034, measured value: 749.4065 (M+H + ). 1 H NMR (600MHz, CDCl 3 )5.00 (1H, brd, J = 1.8Hz), 4.85 (1H, brd, J = 1.8Hz), 4.88 (1H, brs), 4.80 (1H, brd, J = 1.2Hz), 4.48-4.54 (1H, m),4.38(1H,dd,J 1 =9.0Hz,J 2 =4.2Hz), 4.34(1H,dt,J 1 =10.2Hz,J 2 =3.6Hz),3.97-4.09(5H,m),3.94-3.99(1H,m),3.85-3.94(3H,m),3.78-3.85(1H,...

Embodiment 2

[0019] Embodiment two: the preparation of formula II compound (using pyridine hydrochloride) (yield 89%)

[0020]

[0021] Dissolve the compound of formula I (460.0mg, 0.348mmol) in THF (21.5mL) at 20-25°C, add pyridine hydrochloride (201.1mg, 1.74mmol) and TBAF (1M THF solution, 3.48mL, 3.48mmol) , Keep stirring at this temperature for 20h. The reaction solution was concentrated under reduced pressure at 30°C to remove THF, then dissolved in a small amount of DCM, and purified by column chromatography (EA / n-Hept=1 / 1→EA→MeOH / EA=1 / 15) to obtain the target compound of formula II (white solid, 232.1 mg, 88.9%).

Embodiment 3

[0022] Embodiment three: the preparation of formula II compound (comparative experiment, only uses TBAF) (yield 38%)

[0023]

[0024]Dissolve the compound of formula I (460.0mg, 0.348mmol) in THF (21.5mL) at 20-25°C, add TBAF (1M THF solution, 3.48mL, 3.48mmol), and keep stirring at this temperature for 20h. The reaction solution was concentrated under reduced pressure at 30°C to remove THF, then dissolved in a small amount of DCM, and purified by column chromatography (EA / n-Hept=1 / 1→EA→MeOH / EA=1 / 15) to obtain the target compound of formula II (white solid, 99.7mg, 38.2%).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to synthesis of eribulin mesylate, in particular to a method for preparing an intermediate compound II ((1R, 2S, 3S, 4S, 5S, 6R, 11S, 14S, 17S, 19R, 21R, 23S, 25R, 26R, 27S, 31R, 34S)-25-[(2S)-2, 3-dihydroxy]-2, 5-dihydroxy-26-methoxy-19-methyl-13, 20-dimethylene-24, 35, 36, 37, 38, 39-hexaoxaheptacyclo [29.3.1.13, 6.14, 34.111, 14.117, 21.023, 27] nonatriacontane-8, 29-diketone) of eribulin mesylate, which aims to solve the problem of low reaction yield of a traditional synthesis route.

Description

technical field [0001] The invention belongs to the field of chemical synthesis, and specifically relates to the preparation of a key intermediate of complex natural modified drug eribulin mesylate. Background technique [0002] Halichondrin B is a poly(poly)ether macrolide isolated from the scarce Japanese sponge Halichondriaokadai in the 1980s by Japanese scientists Uemura et al. Although halichondrin B only contains three types of C\H\O elements, but the compound structure is very complex. Further studies have found that halichondrin B has a very strong inhibitory effect on cancer cells in vivo and in vitro in mice. Further research by the chemists also found that common sponges such as Phakellia, Lissodendory and Axinella also contain halichondrin B. The National Cancer Institute of the United States has used halichondrin B to conduct systematic activity evaluations in 60 cancer cell lines, and it has been proved that the mechanism of halichondrin B in anti-cancer cell...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D493/22
CPCC07D493/22C07B2200/07
Inventor 邱小龙徐涛左智伟葛杰陆信伟储玲玲刘文博王标顾庭伟王伟伟胡林邹平陈俊曹雷
Owner WISDOM PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap